Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.
abnormalreturns
Tadas Viskanta, Founder and Editor of Abnormal Returns. Author of Abnormal Returns: Winning Strategies from the Frontlines of the Investment Blogosphere.
AllisonLVano
Co-founder of Concept Communications, currently working on PR for StockTwits, tech enthusiast, foodie, wine lover, cook, entertainer and proud mama of two
KeeneOnTheMarketDotCom
Andrew Keene has been an Market Maker. Independent Trader. Founder of KeeneOnTheMarket.com. Regularly Appears on CNBC, Bloomberg, WCIU's First Business & CBOE-TV.
StockCoach
John McLaughlin, StockCoach -
Day Trader (Day Trading Stocks) - Consultant / COACH -
Helping Investor, Swing Trader, and Day Trader LOSERS become profitable WINNERS – Income Potential: $300K+ a year - Dare to Become a Milloinaire !
StockTwitsIR
Deliver real-time, compliant and trackable IR updates and corporate news to your social networks and leading financial portals with StockTwits IR.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class,
... moreoral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival.less
ProActive Capital Resources Group
jramson@proactivecrg.com
750 Lexington Ave., 20th Fl.
New York, NY, 10022
United States of America